Related Experiment Video
Updated: Jun 8, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Advances in systolic heart failure.
Melana Yuzefpolskaya1, Catherine Weinberg, Marrick Kukin
1Division of Cardiology, Department of Medicine, St Luke's Roosevelt Hospital, Columbia University College of Physicians and Surgeons 425, 425 West 59 Street, New York, NY 10019 USA.
F1000 Medicine Reports
|October 16, 2010
Summary
Systolic heart failure impacts millions globally. Advances in understanding pathophysiology and neurohormonal mechanisms have improved medical management, with new trials offering future hope.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Heart failure due to systolic dysfunction presents a significant global health challenge.
- Medical management has evolved considerably over 25 years, driven by pathophysiology and neurohormonal insights.
Purpose of the Study:
- To review current epidemiology and diagnosis of systolic heart failure.
- To discuss current and emerging management strategies.
- To highlight key 2009 trials impacting heart failure care.
Main Methods:
- Literature review of recent and emerging data.
- Analysis of epidemiological and diagnostic trends.
- Discussion of therapeutic advancements and clinical trials.
Main Results:
- Significant progress in understanding heart failure pathophysiology and neurohormonal pathways.
- Identification of key trials (STICH, MADIT-CRT, HeartMate II) influencing 2009 care.
- Overview of evolving diagnostic and management techniques.
Conclusions:
- Continued advancements in medical management are crucial for systolic heart failure.
- Emerging data and clinical trials are shaping future treatment paradigms.
- A comprehensive understanding of epidemiology, diagnosis, and treatment is vital.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...